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A novel triphenyltin(IV) compound with 1-(4-carboxyphenyl)-3-ethyl-3-methylpyrrolidine-2,5-dione was synthesized and
characterized by IR, NMR spectroscopy, mass spectrometry, and elemental analysis. In vitro anticancer activity of ligand precursor
and synthesized organotin(IV) compound was determined against tumor cell lines: human adenocarcinoma (HeLa), human
myelogenous leukemia (K562), and human breast cancer (MDA-MB-453), using microculture tetrazolium test (MTT) assay. 2e
results indicate that complex exhibited very high antiproliferative activity against all tested cell lines with IC50 values in the range
of 0.22 to 0.53 µM. 2e highest activity organotin(IV) compound expressed against the HeLa cells (IC50 � 0.22± 0.04 µM). 2e
ligand precursor did not show anticancer activity (IC50> 200 µM). Furthermore, fluorescence microscopy analysis of HeLa cells
reveal that organotin(IV) complex induced apoptosis as a mode of cell death, which is consistent with the increase of cells in the
sub-G1 phase.
1. Introduction
Metal complexes have been successfully applied in medicine
for the treatment of human diseases such as cancer, rheu-
matoid arthritis, and gastric and duodenal ulcers and also are
in widespread use as imaging agents as diagnostics tools [1].
One of the most expanding areas in medicinal bioinorganic
chemistry is research on the synthesis of new metal-based
compounds and their applications inmedicine as drugs [2‒4].
Nowadays, cancer is one of the most threatening mankind
diseases. During last five decades, over 500,000 synthetic
chemical compounds have been tested for their antitumor
activity, but only about 25 of these are in worldwide use today
[5]. 2e application of the first and most worldwide used
metal-based anticancer drug, cisplatin, discovered by
Rosenberg, is limited by severe side effects such as neuro-,
nephro-, and ototoxicity [6‒11], and therefore, the research of
novel metal-based complexes with reduced toxicity and
improved clinical efficacy is the subject of intensive studies
into anticancer drug investigations [12‒16].
Recent studies have shown very promising in vitro an-
titumor properties of organotin(IV) compounds, against a
wide panel of tumor cell lines of human origin [17‒21]. 2e
organotin(IV) complexes with carboxylate [22‒29], thiolato
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[30‒36], and dithiocarbamato [37] ligands have been ex-
tensively studied, and it was found that (carboxylato)tri-
phenyltin(IV) and tetraorganotin(IV) compounds show the
highest cytotoxic activity [22, 38]. However, the possible
application of the synthesized organotin(IV) derivatives was
very limited due to their poor water solubility [39]. Also,
significant biological studies of organotin(IV) derivatives
with benzoic acids have been reported [40‒46].
Many studies demonstrated that cyclic imides such as
succinimides (pyrrolidine-2,5-diones) have promising bi-
ological properties such as nephrotoxic [47], anticonvulsant
[48], antimutagenic [49], and analgesic [50] activities. Ad-
ditionally, it was found that they inhibit a selective mono-
glyceride lipase and psychiatric disorders such as anxiety and
depression [51]. 2erefore, attention herein was drawn to
aryl-N-succinimide with a carboxylate substituent as ligand
compound. 2ere are numerous reports showing that there
is no single or well-defined number of ways in which
organotin(IV) compounds interact with the cell membrane
or constituents within the cell [52–55].2us, the mechanism
of action of organotin(IV) compounds in effecting cell death
remains unclear, and further work is necessary to identify
the real apoptotic or necrotic pathways that cells treated with
these compounds follow to their death.
In this study, the synthesis and characterization of a
triphenyltin(IV) compound containing 1-(4-carboxyphenyl)-
3-ethyl-3-methylpyrrolidine-2,5-dione anion (CEMPD–) is
reported. 2e evaluation of cytotoxic activity against tumor
cell lines human cervix adenocarcinoma (HeLa), human
myelogenous leukemia (K562), and human breast cancer
(MDA-MB-453) has been performed. Additionally, the mode
of cell death and cell cycle distribution of HeLa cells induced
by synthesized complex were studied.
2. Materials and Methods
2.1.ChemicalsandMethods. 2e ligand 1-(4-carboxyphenyl)-
3-ethyl-3-methylpyrrolidine-2,5-dione, a racemate, was
synthesized as described previously [56]. Elemental analyses
were performed on an elemental vario EL III microanalyzer.
ANicolet 6700 FT-IR spectrometer and ATR technique were
used for recording midinfrared spectra (4000–400 cm−1) for
complex. NMR spectra were recorded on Bruker Avance III
500 spectrometer. Chemical shifts for 1H, 13C, and spectra
were referenced to internal standard TMS. Mass spectra of
the compound were recorded with an Orbitrap LTQ XL
instrument (2ermo Scientific, Bremen, Germany) in
CH3CN [57]. Reagents and solvents were of commercial
reagent grade quality and used without further purification.
2.2. Synthesis of Complex. A suspension of the 1-(4-
carboxyphenyl)-3-ethyl-3-methylpyrrolidine-2,5-dione
(50mg; 0.191mmol) in distilled water (10mL) was treated
with LiOH·H2O (8.1mg; 0.191mmol), the mixture was
stirred for 3 h at 40°C, and a clear solution was formed.2en,
5mL of Ph3SnCl (73.8mg; 0.191mmol) methanolic solution
was added dropwise into the reaction mixture. Afterwards,
the solution was stirred for 3 h and white precipitate was
formed.2e precipitate was filtered off, washed with 5mL of
distilled water, and then dried in vacuo over silica gel.
[Ph3Sn(CEMPD)] yield: 75mg (62%), white solid. Anal.
calcd. for SnC32H29NO4 × 2H2O: C, 59.47; H, 5.15; N, 2.17.
Found: C, 59.60; H, 5.19; N, 2.13. IR (ATR, cm−1): 1716 (s) (]
C�O), 1642 (s) (]a COO–), 1390 (s) (]s COO–), 449 (s) (]
Sn–O). 1H NMR (500MHz, DMSO): |δ| ppm� 7.90 (d, 2H,
–C6H4), 7.86 (m, 6H, o-H in SnPh3, 3J(1H–Sn)� 34Hz), 7.39
(m, 9H, m- and p-H in SnPh3, 5J(1H–Sn)� 77Hz), 7.26 (d,
2H, –C6H4), 2.78–2.62 (AB q, 2H, –C5H2–), 1.70–1.58 (m,
2H, –C2H2CH3), 1.27 (s, 3H, –C3H3), 0.85 (t, 3H,
–CH2C1H3); 13C NMR (125MHz, DMSO): |δ| ppm� 181.92
(C6), 175.32 (C7), 169.35 (C12), 143.46 (C8), 137.58 (C2′
and C6′ in SnPh3, 2J(13C–Sn)� 45Hz), 130.13 (C11), 129.26
(C10), 128.69 (C1′ in SnPh3, 1J(13C–Sn)� 67Hz), 127,01
(C3′ and C5′ in SnPh3), 44.12 (C4), 127.01 (C9), 40.39 (C5),
31.27 (C2), 23.32 (C3), 8.85 (C1). HR ESI–MS (CH3CN),m/
z: 634.10257 [M + Na]+; 650.07690 [M + K]+.
2.3. Preparation of Drug Solutions. DMSO (Sigma-Aldrich,
St. Louis, MO, USA) was used for preparation of stock
solutions for investigated compounds at the concentration
of 10mM. Afterwards, various working concentrations were
prepared from the stock solutions diluting with the nutrient
medium. 2e nutrient medium was RPMI-1640 (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 2mML
glutamine, 10% fetal bovine serum (FBS; Biochrom AG,
Berlin, Germany), and 1% penicillin/streptomycin (Sigma-
Aldrich, St. Louis, MO, USA) [57].
2.4. Cell Lines. Human cervix adenocarcinoma cell line
(HeLa), human chronic myelogenous leukemia cells (K562),
and human breast cancer cell line (MDA-MB-453) were
grown in complete RPMI-1640 medium (Sigma-Aldrich, St.
Louis, MO, USA) as indicated in [57].
2.5. Determination of Cell Survival. Similarly to methods
described in [57], HeLa (2500 cells/well) and MDA-MB-
453 cells (3000 cells/well) were seeded into the wells of a 96-
well flat-bottomed microtiter plate. Twenty-four hours later,
after the cell adherence, different concentrations of in-
vestigated compounds were added to the wells, except for the
controls, where only the complete medium was added. 2e
final complex concentration range used in the experiments
was 0.0625–1 µM (0.0625, 0.125, 0.25, 0.5, and 1 µM). 2e
ligand concentration range used was 12.5–200 µM.2e final
concentration of DMSO was negligible for complex and
never exceeded 1% for ligand, which is a nontoxic con-
centration for the cells [57]. For nonadherent K562 cells
(5000 cells/well), the compounds were applied 2 h after cell
seeding. 2e culture medium with corresponding concen-
trations of investigated compounds, but without cells,
was used as blank. 2e cultures were incubated for 72 h, and
the effects of the investigated compounds on cancer cell
survival were determined using the microculture tetrazo-
lium test (MTT), according to Mosmann [58] with modi-
fication by Ohno and Abe [59], 72 h after the addition of the
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investigated compounds. Briefly, 20 μL of MTT solution
(5mg/mL of phosphate-buffered saline, PBS) was added to
each well. Samples were incubated for additional 4 h at 37°C
in a humidified atmosphere of 5% CO2 (v/v). Afterward,
100mL of 10 sodium dodecyl sulfate (SDS) was added in
order to extract the insoluble formazan, which represents the
product of the conversion of theMTTdye by viable cells.2e
number of viable cells in each well is proportional to the
intensity of the absorbance (A) of light, which was measured
in a microtiter plate reader at 570 nm, 24 h later [57]. To
determine cell survival (%), the A of a sample with cells
grown in the presence of various concentrations of the
investigated compounds was divided by the control optical
density (the A of control cells grown only in the nutrient
medium) and multiplied by 100. 2e A of the blank was
always subtracted from the A of the corresponding sample
incubated with the target cells. IC50 is defined as the con-
centration of an agent inhibiting cell survival by 50%
compared with the vehicle-treated control [57]. All
experiments were performed in technical and biological
triplicates.
2.6. Morphological Analysis (AO/EB Double Staining).
2e mode of cell death induced by investigating compound
was assessed with acridine orange (AO) and ethidium
bromide (EB) double staining assay, according to the
standard procedures and examined under a fluorescence
microscope [60]. HeLa cells were seeded overnight on
coverslips (100,000 cells/coverslip) in 2mL of complete
medium. 2e following day, cells were treated with complex
in concentrations corresponding to 2 × IC50 and 4 × IC50 for
the 72 h treatment. After 24 h, coverslips with target cells
were stained with the acridine orange/ethidium bromide
mixture (3 μg/mL AO and 10 μg/mL EB in PBS) and visu-
alized and photographed under a fluorescence microscope
(fluorescence microscope-PALM MicroBeam systems, Carl
Zeiss, Oberkochen, Germany) [57].
2.7. Cell Cycle Analysis. HeLa cells were seeded in six-well
plates (3 × 105 cells/well) and after 24 h of incubation treated
with [Ph3Sn(CEMPD)] (2 × IC50 concentration) at 37°C for
the additional 24 or 48 h. 2e assay was performed as de-
scribed in [57]. In short, after the incubation period, the cells
were collected by trypsinization, fixed in ice-cold 70% ethanol
for 1 h on ice, and incubated at −20°C for one week.2en, the
cells were washed in PBS, and pellets obtained by centrifu-
gation were treated with RNAse (100 μg/mL) at 37°C for
30min and incubated with propidium iodide (PI) (40 μg/mL)
for at least 30min [57]. DNA content and cell-cycle distri-
bution were analyzed using Becton Dickinson FACSCalibur
flow cytometer. Flow cytometry analysis was performed using
CellQuest (Becton Dickinson, San Jose, CA, USA) software
with a minimum of 20,000 cells per sample [61].
3. Results and Discussion
3.1. Synthesis and Characterization. In the reaction of
Ph3SnCl and equimolar amount of 1-(4-carboxyphenyl)-3-
ethyl-3-methylpyrrolidine-2,5-dione, previously deproto-
nated with LiOH, the desired compound [Ph3Sn(CEMPD)]
was obtained as white product in moderate yield. 2e
prepared compound was soluble in dichloromethane,
chloroform, dimethyl sulfoxide, and acetonitrile. 2e syn-
thesized compound was characterized by elemental analysis,
IR, NMR spectroscopy, and mass spectrometry.
IR spectra of the synthesized compound showed strongν(C�O) stretching band at 1716 cm−1 which was similar to
the ligand precursor [56], indicating that coordination of
carbonyl oxygen atoms to the tin(IV) center did not occur.
Additionally, strong bands were found at 1642 and
1390 cm−1 which correspond to the asymmetric and sym-
metric vibrations, respectively, of the COO moiety (ligand
precursor: 1682 and 1390 cm−1). Moreover, the difference
between the asymmetric and symmetric vibrations of more
than 200 cm−1 indicates monodentate coordination of the
carboxylate ligand to tin(IV) center [62]. 2e medium ab-
sorptions corresponding to the Sn–O stretching mode of
vibration appear at 449 cm−1.
In the 1H NMR spectra, a set of two signals arising from
the o-H andm-/p-H atoms of SnPh3 moiety, at ca. 7.86 and
7.39 ppm, respectively, were observed. Furthermore, ali-
phatic protons of methyl and ethyl groups from the suc-
cinimide ring are on their anticipated positions [56].
Expectedly, methyl protons resonated as one strong singlet
at 1.27 ppm, while those from the ethyl group were ob-
served as multiplet (1.70–1.58 ppm) and triplet (0.88 ppm).
Additionally, methylene protons in the succinimide ring
(−CH2−) were found as characteristic AB quartet in the
range 2.78–2.62 ppm. Coupling with tin nucleus can be
observed as satellites nearby resonances of o-H atoms from
the Ph3Sn moiety. 13C NMR spectra of the synthesized
compound showed expected signals at the appropriate
positions. Numeration of carbon atoms is shown in
Scheme 1. All carbonyl carbons are resonating at values
higher than 160 ppm. Aromatic carbon atoms can easily be
assigned due to visible coupling with tin through one (ipso-
C) and two (o-C) bonds. Furthermore, HR ESI-MS was
recorded in positive ion mode, and the [M + Na]+ and [M +
Na]+ mass peak were detectable. Complete characterization
of the synthesized compound can be seen in supplementary
section (Figures S1–S7).
3.2. In Vitro Cytotoxicity. 2e cytotoxic potential of ligand
precursor 1-(4-carboxyphenyl)-3-ethyl-3-methylpyrrolidine-
2,5-dione (CEMPDH) and its new synthesized organotin(IV)
compound, [Ph3Sn(CEMPD)], was studied in a panel of
malignant cell lines. In Figure 1 the survival of HeLa, K562,
andMDA-MB-453 in the presence of different concentrations
of complex are presented. 2e IC50 values for CEMPDH,
[Ph3Sn(CEMPD)] and cisplatin, for comparison, against in-
vestigated cell lines are summarized in Table 1 (MTTtest, 72 h
incubation). Cisplatin was used as a positive control. 2e
results indicate that the ligand precursor CEMPDH did not
show cytotoxic activity against all tested cell lines
(IC50> 200 µM). On the other hand, [Ph3Sn(CEMPD)] ex-
hibits high activity against all three malignant cell lines, the
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highest against HeLa cells and the lowest IC50 value observed
against K562 cells. In comparison with cisplatin (Table 1), the
IC50 value of [Ph3Sn(CEMPD)] ranges from 0.22 to 0.53 µM
and novel organotin(IV) compound is 11 up to 31 times more
active. Furthermore, the activity of [Ph3Sn(CEMPD)] is in
expected range for (carboxylato)triphenyltin(IV) compounds
[28, 63]. It is well known that some analogue [Ph3Sn(RCOO)]
compounds (e.g., RCOO 4-methoxyphenylacetato, 2,5-
dimethyl-3-furoato, or 1,4-benzodioxane-6-carboxylato) may
possess relatively high selectivity towards K562 tumor cells
[28]. Namely, they can be up to four times more active against
the K562 tumor cell line than that on normal rested or
stimulated peripheral blood mononuclear cells (PBMCs).
us, further studies should concern the activity of
[Ph3Sn(CEMPD)] against normal cells.
3.3. Morphological Analysis of HeLa Cell Death. To de-
termine themode of cell death induced by [Ph3Sn(CEMPD)]
in HeLa cell line, AO/EB double staining assay was per-
formed. Selected cell line was treated for 24 h with the
concentrations of the investigated compound corresponding
to 2 × IC50 and 4 × IC50 values obtained in MTT assay. e
results from uorescence microscopy of treated HeLa cells
are showed in Figure 2.
Treatment of HeLa cells for 24 h with [Ph3Sn(CEMPD)]
(2 × IC50) induced nuclear condensation detected by freely
permeable dye AO, which is a typical morphological feature
of apoptosis. Higher concentration of [Ph3Sn(CEMPD)] (4 ×
IC50) induced a signicantly higher level of apoptosis, pri-
marily nuclear fragmentation. Furthermore, a typical feature
correlated to late apoptosis, damage of the plasma mem-
brane, could be detected by the entry of the EB into the cell
and binding to the DNA (red uorescence).
3.4. Cell Cycle Analysis. Based on the results described
above, to further examine the mechanisms of action of
[Ph3Sn(CEMPD)] in HeLa cells, determination of cell cycle
distribution was performed on the basis of DNA content in
HeLa cell line, after exposure for 24 and 48 h by ow
cytometry analysis (PI staining). As shown in Figure 3, after
exposure of HeLa cells to [Ph3Sn(CEMPD)] in concentra-
tion corresponding to 2× IC50, number of cells in sub-G1
increases signicantly in comparison with control cells (24/
48 h: 1.62/3.68%, control; 9.0/10.11%, [Ph3Sn(CEMPD)]).
After 48 h of incubation, there is a small increase in the
number of cells in the sub-G1 phase (relative to 24 h), but
also a decrease in the number of cells in the S and G2/M
stages relative to the control cells. It could be that cells in the
S and G2/M phase are more susceptible to apoptotic stimuli
than those in the G1 phase.
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Scheme 1: Synthesis of complex [Ph3Sn(CEMPD)].
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Figure 1: Survival of tumor cells as a function of di¡erent con-
centrations of [Ph3Sn(CEMPD)] determined by MTT test, after
72 h incubation.
Table 1: IC50 (µM) (mean± SD) of CEMPDH, [Ph3Sn(CEMPD)],
and cisplatin (72 h of action).
Compounds
IC50 (µM)
HeLa K562 MDA-MB-453
CEMPDH >200 >200 >200
[Ph3Sn(CEMPD)] 0.22± 0.04 0.53± 0.01 0.28± 0.03
Cisplatin 6.90± 1.71 5.82± 0.17 6.73± 0.48
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4. Conclusion
e synthesis of a new triphenyltin(IV) complex with 1-(4-
carboxyphenyl)-3-ethyl-3-methylpyrrolidine-2,5-dione,
[Ph3Sn(CEMPD)] is described. e compound was char-
acterized by elemental analysis, IR, 1H, 13C NMR spectros-
copy, and mass spectrometry. [Ph3Sn(CEMPD)] along with
appropriate acid CEMPDH was tested against human ade-
nocarcinoma (HeLa), human myelogenous leukemia (K562),
and human breast cancer (MDA-MB-453), by MTT assay.
e results have shown that [Ph3Sn(CEMPD)] expressed
excellent cytotoxicity against all mentioned cancer cell lines
with the IC50 range from 0.22 to 0.53 µM which is 11 to 31
times higher in comparison with clinically used anticancer
drug cisplatin. Nevertheless, the ligand precursor did not
show cytotoxic activity (IC50> 200 µM). Additionally, the
mode of HeLa cell death induced by synthesized complex
was apoptosis, seen as condensation and fragmentation of
nuclei, which is consistent with the results of ow
cytometry and increase of number of cells in the sub-G1
phase of the cell cycle after 24 h treatment scheme. e
e¡ects of [Ph3Sn(CEMPD)] towards cancer cells indicate
the necessity for further studies with in vitro and/or pre-
sumably in vivo tests.
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Figure 2: Fluorescent micrographs of acridine orange and ethidium bromide stained HeLa cells, untreated (a) or treated with
[Ph3Sn(CEMPD)] for 24 h (b) 2 × IC50 and (c) 4 × IC50. Arrows indicate apoptotic cells with condensed chromatin and/or fragmented nuclei
while arrowheads mark necrotic cells.
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Figure 3: E¡ect of [Ph3Sn(CEMPD)] on cell cycle phase distribution: HeLa cell lines were exposed to IC50 doses of organotin(IV)
compound.
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Supplementary Materials
Figure S1. 1HNMR spectrum of [Ph3Sn(CEMPD)]. Figure S2.
13C NMR spectrum of [Ph3Sn(CEMPD)]. Figure S3. coupling
of protons with tin observed in 1H NMR spectrum of
[Ph3Sn(CEMPD)]. Figure S4. coupling of carbon atoms with
tin observed in 13C NMR spectrum of [Ph3Sn(CEMPD)].
Figure S5. IR spectrumof [Ph3Sn(CEMPD)]. Figure S6. HRESI
mass spectrum of [Ph3Sn(CEMPD)]; [M+Na]+ (634.10257).
Figure S7. HR ESI mass spectrum of [Ph3Sn(CEMPD)];
[M+K]+ (650.07690). (Supplementary Materials)
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